Latest Hotspot

AstraZeneca has agreed to pay Bristol-Myers Squibb $510 million to resolve patent disputes

4 August 2023
3 min read

On August 1, 2023, AstraZeneca has reached an agreement to pay $510 million to BMS to resolve patent lawsuit over its PD-L1 mAb Imfinzi (Durvalumab) and CTLA-4 mAb Imjudo (Tremelimumab). 

In March 2022, BMS first filed lawsuits claiming that Imfinzi (Durvalumab) infringed at least 8 patents related to Opdivo (Nivolumab), and added claims of PD-1 patent infringement in another lawsuit in April. In January, just three months after Imjudo (Tremelimumab) went on the market, BMS filed another lawsuit against AstraZeneca for infringing on patents related to Yervoy (Ipilimumab). AstraZeneca spokesperson said the company chose to spend $510 million to resolve all patent disputes with BMS and its partner Ono Pharmaceutical over the two drugs. According to AstraZeneca’s 2023 H1 financial report, Imfinzi had sales of $1.976 billion in the first half of the year, up 57% YoY; Imjudo also has good market potential. It is a wise decision to pay patent fees in order to facilitate subsequent commercialization of the two drugs.

For pharmaceutical companies, antibodies targeting PD-1/PD-L1 would likely struggle to avoid patents held by BMS and Ono Pharmaceutical if they seek to sell in markets such as the USA and Europe. Almost any use of antibody drugs related to PD-1/PD-L1 immune suppressant signals will infringe on patents held by BMS and Ono. Prior to AstraZeneca, pharmaceutical companies including Merck, Roche, and others chose to settle with BMS. Merck’s settlement agreement with Ono stipulates that from 2017 to 2023, Merck must pay a 6.5% sales split on Keytruda. From 2024 to 2026, the payment percentage drops to 2.5%. BMS and Ono split the additional revenue equally in a 3:1 ratio. Roche also spent a large sum of money for settlement. In 2020, BMS, Ono and Roche agreed on a global patent license agreement for Roche’s anti-PD-L1 antibody Tecentriq. According to the agreement, Roche paid $324 million, with additional annual single-digit royalties on worldwide net sales until 2026.

图形用户界面, 文本, 应用程序

描述已自动生成

According to information disclosed by Synapse (click the card below to access the PD-1 target login after registration to get free detailed information on the drug under this target, indication, R&D agency, clinical trials, etc.), as of August 3, 2023, there are 302 drugs under development targeting PD-1, including 270 indications, 332 R&D agencies, with 7556 related clinical trials, and up to 53789 patents…PD-1/PD-L1 is one of the hottest areas of R&D, and has successively produced numerous blockbuster drugs, including the $20 billion sales of Keytruda. With their related patents, BMS and Ono can collect substantial fees, demonstrating the importance of proper patent layout for new drug development.

The oral TNF-α drug MYMD-1 of MyMD Pharmaceuticals has reached phase 2 clinical end points
Latest Hotspot
2 min read
The oral TNF-α drug MYMD-1 of MyMD Pharmaceuticals has reached phase 2 clinical end points
3 August 2023
On August 1, 2023, MyMD Pharmaceuticals announced that the oral Tumor Necrosis Factor-α (TNF-α) inhibitor MYMD-1 achieved statistically significant positive results in a Phase 2 randomized clinical trial (NCT05283486).
Read →
Sumitomo Dainippon Pharma/Otsuka Pharmaceutical announced that two Phase III studies of Ulotaront did not meet the primary endpoints
Latest Hotspot
2 min read
Sumitomo Dainippon Pharma/Otsuka Pharmaceutical announced that two Phase III studies of Ulotaront did not meet the primary endpoints
3 August 2023
On July 31, 2023, Sumitomo Dainippon Pharma and Otsuka Pharmaceutical jointly announced that their two Phase III studies, DIAMOND 1 and DIAMOND 2, for ulotaront (SEP-363856) in the treatment of acute schizophrenia did not meet the primary endpoints.
Read →
Astellas files NDA in China for CLDN18.2-targeted new drug Zolbetuximab
Latest Hotspot
3 min read
Astellas files NDA in China for CLDN18.2-targeted new drug Zolbetuximab
3 August 2023
On August 1, 2023, the official website of the Chinese Drug Evaluation Center (CDE) shows that the new drug application (NDA) for Zolbetuximab injection developed by Astellas has been accepted for review.
Read →
GSK's PD-1 inhibitor Dostarlimab combined with chemotherapy for the treatment of dMMR endometrial cancer receives FDA approval
Latest Hotspot
3 min read
GSK's PD-1 inhibitor Dostarlimab combined with chemotherapy for the treatment of dMMR endometrial cancer receives FDA approval
3 August 2023
Dostarlimab is the first immunotherapy approved by the FDA to be used in combination with chemotherapy for the first-line treatment of this patient population.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.